Photo from Nagashree Seetharamu/X
Apr 29, 2024, 05:46
Nagashree Seetharamu: Navigating Treatment Beyond 3 Years of Survival in Metastatic EGFR+ NSCLC
Nagashree Seetharamu, Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared a post on X/Twitter:
”Are people getting denials from insurance for treatment beyond 3 years of overall survival interval in metastatic setting (EFGR+ NSCLC) despite sending all the necessary documents?
Writing an appeal letter and trying to maintain professionalism.”
Source: Nagashree Seetharamu/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56